CA-SCIENTIST.COM
Scientist.com, the pharma industry’s leading research marketplace, and PhenoVista, a life sciences services company developing and implementing multiplexed, high content imaging-based phenotypic assays for target validation, lead optimization, and mechanism of action studies, have launched the biotech industry’s first digital eShop for exploring and purchasing phenotypic studies.
The digital storefront makes it easy for scientists to design complex research projects, get feedback from PhenoVista’s experts, determine pricing, and then purchase and manage projects. What previously could require hours of face-to-face meetings or video calls can now be accomplished online in much less time. The Shopify-like virtual store was created by Scientist.com and is designed to make it as easy to purchase complex assay services as it is to buy products and reagents.
“Today, almost half of the $240B spent annually on drug research is performed by companies like PhenoVista that offer highly technical and specialized custom assay services,” said Kevin Lustig, PhD, CEO and Founder at Scientist.com. “With the launch of PhenoVista’s online store, researchers get more immediate access to their services and expertise, allowing them to accelerate crucial experiments and benefit from the use of data-rich phenotypic studies.”
There are significant advantages offered by high-plex phenotypic studies across the entire R&D workflow as compared to conventional, low-plex in vitro assays.
“High-stakes decision making is at the heart of R&D, and uncertainty about targets, mechanisms of action, and whether to advance or abandon candidate compounds is the norm,” said James G. Evans, CEO and Founder of PhenoVista. “With expertise in high-content imaging-based phenotypic studies, we deliver the biological insights and high-quality data needed to inform and de-risk these decisions. We are excited to leverage the marketplace experience established by Scientist.com to create our virtual storefront and bring added convenience to researchers in the biotech industry.”
The virtual storefront can be accessed at https://store.phenovista.com/.
About Scientist.com
Scientist.com is a privately held San Diego-based company on a mission to make it faster and cheaper to discover new medicines. At its heart is an AI-powered marketplace that helps drug researchers use innovative technologies to rapidly translate their ideas into actionable data. Through Scientist.com, scientists communicate directly with research experts at over 4,000 global laboratories to design and execute complex research experiments. Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram.
About PhenoVista
Founded in 2014, PhenoVista is a leader in the development and implementation of multiplexed, high content imaging-based phenotypic assays for biopharmaceutical clients. These assays deliver the high-quality, quantitative data needed to inform and de-risk critical R&D decisions with greater confidence. Clients gain access to novel insights related to the complex biology underlying target validation, therapeutic delivery, efficacy and safety, cytotoxicity, and mechanisms of action, increasing the likelihood of success of first-in-class drug candidates. To learn more, visit our website www.phenovista.com or see us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214355636/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma17.12.2025 17:20:00 CET | Press release
Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab is the first CD19- and CD20-dual-targeted immunotherapy combination regimen approved for eligible patients in Europe with relapsed or refractory FLPatients with relapsed or refractory FL achieved significantly improved progression-free survival with Minjuvi in combination with rituximab and lenalidomide in the Phase 3 inMIND registration trialIn Western countries, including Europe, relapsed or refractory FL affects 2-4 out of every 100,000 people1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at least one line of systemic therapy. "The EC approval of Minjuvi addresses a critical need, bringing a new, first-of-its-kind, chemotherapy-free option to patients in Europe with relapsed or refractory FL,” said Bi
Rigaku Launches ONYX 3200, a Metrology Instrument for Semiconductor Manufacturing17.12.2025 16:00:00 CET | Press release
Enables complete metal inspection for all processes from chip wiring to advanced packaging on a single platform Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) announced the launch of the ONYX 3200, a new semiconductor metrology system to measure film thickness, composition and bump* structures for wafer-level processes. The system is engineered to help manufacturers stabilize quality and increase yield in the metal-wiring formation (back-end-of-line (BEOL)) and packaging processes of semiconductor chips. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216597402/en/ ONYX 3200 Due to accelerating demands for AI, high-performance computing, data centers, mobile devices, and other devices, chip wiring and interconnect structures have grown increasingly delicate and complex. As a
Taylor Wessing Diversifies Its International Strategy17.12.2025 15:05:00 CET | Press release
International law firm Taylor Wessing is set to diversify its strategy within its international alliance, in order to push international growth and innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217415857/en/ Dr. Oliver Bertram, Global Co-Chair at Taylor Wessing The English part of the partnership is seeking a merger with US law firm Winston & Strawn and would – depending on a corresponding partner decision, which is still pending – leave the Taylor Wessing alliance at the end of April 2026. Both parties wish to continue their successful joint international client work unchanged. Therefore, collaboration between Taylor Wessing and future Anglo-American firm Winston Taylor will continue seamlessly based on a cooperation agreement, ensuring that clients will not experience any change in their collaboration with Taylor Wessing. With the firm’s new open strategy, Taylor Wessing equally meets the strategic requirem
ISACA to Lead Global Credentialing for CMMC Cybersecurity Framework as International Cyber Readiness Standards Rise17.12.2025 15:00:00 CET | Press release
ISACA appointed to certify professionals assessing organisations against the US Department of War’s (DoW) Cybersecurity Maturity Model Certification (CMMC) programme.New requirements mean that all global businesses supplying to US DoW will need to be compliant with this framework, impacting over 200,000 organisationsAppointment supports global demand for consistent, verifiable cyber maturity amid escalating cyber threats and growing assessor shortages.The Cyber AB remains the official accreditation body for the CMMC programme, authorizing the CAICO and other CMMC ecosystem parties As cyber threats escalate and governments raise expectations around operational resilience, ISACA has been appointed to lead the global credentialing programme for the U.S. DoW’s Cybersecurity Maturity Model Certification (CMMC) program. The appointment positions ISACA – the international association for cybersecurity, audit and digital trust – as the exclusive CMMC Assessor and Instructor Certification Organ
ASN Bank Signs a Contract With HCLTech to Accelerate Digital Transformation and Enhance Customer Experience17.12.2025 14:43:00 CET | Press release
HCLTech, a leading global technology company, today announced that it has been selected as a strategic partner by ASN Bank (formerly de Volksbank), the fourth-largest retail bank in the Netherlands. As part of its new strategy ‘Simplify and Grow’, ASN Bank aims to modernise and standardise its IT architecture, which will involve consolidating IT services, simplifying the vendor landscape and building a future-ready organisation. Under the multi-year agreement, HCLTech will support ASN Bank’s enterprise applications, and streamline services through a distributed delivery model to enhance efficiency and customer experience. Michel Ruijterman, Chief Information Officer, ASN Bank: “By signing this agreement , HCLTech’s proven track record in delivering scalable, innovative solutions tailored to the financial services sector means we can now confidently press on with streamlining our business by reducing the number of existing products and aligning the underlying processes and systems under
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom